Key facts
- This page summarizes Amit Sachdev's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2023, 16:05.
Amit Sachdev - 10 Aug 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- EVP, Chief Patient Officer
- Issuer ticker
- VRTX
- Reported as of
- 10 Aug 2023
- Net transaction value
- -$3,510,850
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2023, 16:05:14 UTC
- Prior SEC filing
- 03 Mar 2023
- Next SEC filing
- 17 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amit Sachdev filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 14 Aug 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2023.
- Current net transaction value: -$3,510,850.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Sale
- Transaction value
- $3,510,850
- Shares
- -10,031
- Change %
- -15%
- Price
- $350.00
- Shares after
- 58,814
- Date
- 10 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 882
- Date
- 10 Aug 2023
- Ownership
- 401(k)
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,565
- Date
- 10 Aug 2023
- Ownership
- Held in Trust
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 1 footnote
Footnote F1
Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.